immunogen


Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.
Related to immunogen: hapten, Tolerogen

immunogen

[ə′myü·nə·jən]
(immunology)
A substance which stimulates production of specific antibody or of cellular immunity, and which can react with these products.
References in periodicals archive ?
Under terms of the agreement between ImmunoGen and SB, in addition to royalties, ImmunoGen could receive up-front cash and milestone payments totaling more than $40 million.
Blattler, 45, had been Vice President, Research, at ImmunoGen since 1987, when the Company moved its research out of Dana-Farber Cancer Institute and established its own laboratories.
CONTACT: Mark Ratner, director, external communications, of ImmunoGen, 617-661-9312/
Small-drug immunoconjugates using humanized antibodies will be used as tumor debulking agents," adds ImmunoGen CEO Sayare "and therefore will complement our Oncolysin products, which are designed to prevent relapses once a patient is in remission.
Over all, ImmunoGen has four Oncolysin conjugates in clinical trials in the treatment of various types of cancer.
Roussel-Uclaf had been working with ImmunoGen since 1989," states Mitchel Sayare, ImmunoGen chairman and chief executive officer.
Oncolysin CD6 is the fourth product ImmunoGen has brought into the clinic successfully," states Mitchel Sayare, chairman and chief executive officer.
May 17 /PRNewswire/ -- Clinical investigators have seen evidence of efficacy in the recently completed Phase I clinical trial of ImmunoGen, Inc.
ImmunoGen expects enrollment to be completed in one year and to be in position to prepare a Product License Application six to 18 months after that, in 1995.
Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.
Using the information obtained in this study, ImmunoGen will begin a dose-ranging Phase I/II clinical trial in patients who are in remission following conventional chemotherapy, to extend their period of disease- free survival.